TrypsiNNex^® poster for influenza virus production

In cell culture-based manufacturing of influenza vaccines, trypsin plays an important role in activating the produced influenza virus particles. The trypsin used can influence cell culture integrity and production consistency. Despite meticulous raw materials testing, using animal-derived trypsin carries the risk of adventitious contaminants, and infection of cell cultures has potentially serious consequences for patients and production continuity. Furthermore, most trypsin products exhibit autolytic activity that rapidly degrades the enzyme, leading to subpar and variable performance.

The new enzyme TrypsiNNex^®; addresses safety and consistency. First, TrypsiNNex^® is a recombinant trypsin produced in line with industry standards for non-animal origin reagents that eliminate contamination by adventitious agents or impurities. Second, TrypsiNNex^® is expressed as an inactive protein and activated shortly before stabilization. As a result, TrypsiNNex^® has a high and stable proportion of intact β-trypsin, making it well-suited for influenza virus production.

Here, we show how TrypsiNNex^® can optimize the production of two influenza strains, H1N1 and H3N2, in the engineered Mardin-Darby Canine Kidney (MDCK)-SIAT1 cell line. We also compare the performance of TrypsiNNex^® in promoting virus propagation to other commercial trypsin products.